As of January 22, 2025, Affimed (AFMD) has a market cap of $18.032 million USD. According to our data, Affimed is ranked No.8649 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $18.03 M |
-7.56%
|
Dec 31, 2024 | $19.51 M |
-80.96%
|
Dec 29, 2023 | $0.10 B |
-49.60%
|
Dec 30, 2022 | $0.20 B |
-77.54%
|
Dec 31, 2021 | $0.90 B |
-5.15%
|
Dec 31, 2020 | $0.95 B |
112.41%
|
Dec 31, 2019 | $0.45 B |
-11.90%
|
Dec 31, 2018 | $0.51 B |
139.23%
|
Dec 29, 2017 | $0.21 B |
-27.78%
|
Dec 30, 2016 | $0.30 B |
-74.72%
|
Dec 31, 2015 | $1.17 B |
14.84%
|
Dec 31, 2014 | $1.02 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Genmab
GMAB
|
$13.32 B |
0.000 M
|
Denmark
|
MacroGenics
MGNX
|
$0.19 B |
-0.000 M
|
USA
|
Xencor
XNCR
|
$1.45 B |
0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Autolus Therapeutics
AUTL
|
$0.57 B |
0.000 M
|
UK
|
Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Market Cap | = | AFMD Stock Price | * | AFMD Shares Outstanding |
= | $1.10 | * | 16.39 M | |
= | $18.03 M |